AU2006232129B2 - Crystalline form of a quinolinone-carboxamide compound - Google Patents

Crystalline form of a quinolinone-carboxamide compound Download PDF

Info

Publication number
AU2006232129B2
AU2006232129B2 AU2006232129A AU2006232129A AU2006232129B2 AU 2006232129 B2 AU2006232129 B2 AU 2006232129B2 AU 2006232129 A AU2006232129 A AU 2006232129A AU 2006232129 A AU2006232129 A AU 2006232129A AU 2006232129 B2 AU2006232129 B2 AU 2006232129B2
Authority
AU
Australia
Prior art keywords
crystalline
salt form
crystalline salt
oxo
isopropyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2006232129A
Other languages
English (en)
Other versions
AU2006232129A1 (en
Inventor
Robert Chao
Paul R. Fatheree
Daniel Genov
Adam Goldblum
S. Derek Turner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alfasigma SpA
Original Assignee
Alfasigma SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alfasigma SpA filed Critical Alfasigma SpA
Publication of AU2006232129A1 publication Critical patent/AU2006232129A1/en
Application granted granted Critical
Publication of AU2006232129B2 publication Critical patent/AU2006232129B2/en
Assigned to THERAVANCE BIOPHARMA R&D IP, LLC reassignment THERAVANCE BIOPHARMA R&D IP, LLC Request for Assignment Assignors: THERAVANCE, INC.
Assigned to ALFASIGMA S.P.A. reassignment ALFASIGMA S.P.A. Request for Assignment Assignors: THERAVANCE BIOPHARMA R&D IP, LLC
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2006232129A 2005-04-06 2006-04-05 Crystalline form of a quinolinone-carboxamide compound Expired AU2006232129B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66878005P 2005-04-06 2005-04-06
US60/668,780 2005-04-06
PCT/US2006/012978 WO2006108127A2 (en) 2005-04-06 2006-04-05 Crystalline form of a quinolinone-carboxamide compound

Publications (2)

Publication Number Publication Date
AU2006232129A1 AU2006232129A1 (en) 2006-10-12
AU2006232129B2 true AU2006232129B2 (en) 2012-07-12

Family

ID=37074104

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006232129A Expired AU2006232129B2 (en) 2005-04-06 2006-04-05 Crystalline form of a quinolinone-carboxamide compound

Country Status (29)

Country Link
US (4) US7728004B2 (enExample)
EP (1) EP1874766B1 (enExample)
JP (2) JP5230407B2 (enExample)
KR (1) KR101322873B1 (enExample)
CN (1) CN101151264B (enExample)
AR (2) AR053208A1 (enExample)
AT (1) ATE479682T1 (enExample)
AU (1) AU2006232129B2 (enExample)
BR (1) BRPI0610657A2 (enExample)
CA (1) CA2603654C (enExample)
CY (1) CY1111275T1 (enExample)
DE (1) DE602006016586D1 (enExample)
DK (1) DK1874766T3 (enExample)
EA (1) EA012115B1 (enExample)
ES (1) ES2350495T3 (enExample)
HR (1) HRP20100629T1 (enExample)
IL (1) IL186023A (enExample)
MA (1) MA29403B1 (enExample)
MX (1) MX2007012438A (enExample)
MY (1) MY151075A (enExample)
NO (1) NO339699B1 (enExample)
NZ (1) NZ561900A (enExample)
PE (1) PE20061310A1 (enExample)
PL (1) PL1874766T3 (enExample)
PT (1) PT1874766E (enExample)
SI (1) SI1874766T1 (enExample)
TW (1) TWI377206B (enExample)
WO (1) WO2006108127A2 (enExample)
ZA (1) ZA200708071B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7063671B2 (en) * 2002-06-21 2006-06-20 Boston Scientific Scimed, Inc. Electronically activated capture device
US7728006B2 (en) * 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
TWI351282B (en) 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
DE602005016446D1 (de) * 2004-11-05 2009-10-15 Theravance Inc 5-HT4-Rezeptoragonistenverbindungen
DE602005014566D1 (de) 2004-11-05 2009-07-02 Theravance Inc Chinolinon-carboxamid-verbindungen
TWI377206B (en) * 2005-04-06 2012-11-21 Theravance Inc Crystalline form of a quinolinone-carboxamide compound
PT2404919E (pt) 2005-11-08 2013-10-22 Vertex Pharma Composto heterocíclico útil como um modulador de transportadores de cassete de ligação a atp
JP2010527357A (ja) * 2007-05-17 2010-08-12 セラヴァンス， インコーポレーテッド 腸の前処置のための運動促進剤
CH698729B1 (de) * 2007-05-30 2009-10-15 Cerbios Pharma Sa Stabile, kristalline (6S)-N(5)-Methyl-5, 6,7,8-tetrahydrofolsäure.
HUE049642T2 (hu) * 2007-12-07 2020-09-28 Vertex Pharma 3-(6-(1-(2,2-Difluorbenzo[d][1,3]dioxol-5-il)-ciklopropánkarboxamido)-3-metilpiridin-2-il)-benzoesav szilárd formái
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
LT2419104T (lt) 2009-04-13 2018-02-12 Theravance Biopharma R&D Ip, Llc 5-ht4 receptoriaus agonistų ir acetilcholinesterazės inhibitorių deriniai, skirti pažinimo sutrikimų gydymui
CN102762572A (zh) 2010-02-01 2012-10-31 诺瓦提斯公司 作为CRF-1受体拮抗剂的吡唑并[5,1b]*唑衍生物
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
EP2531490B1 (en) 2010-02-02 2014-10-15 Novartis AG Cyclohexyl amide derivatives as crf receptor antagonists
ES2900353T3 (es) 2010-04-07 2022-03-16 Vertex Pharma Composiciones farmacéuticas de ácido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiriidin-2-il)benzoico y administración de las mismas
NZ727015A (en) 2012-01-25 2017-12-22 Vertex Pharma Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
CA2930199C (en) 2013-11-12 2022-10-25 Vertex Pharmaceuticals Incorporated Process of preparing pharmaceutical compositions for the treatment of cftr mediated diseases
CA3069989C (en) 2017-07-31 2025-05-06 Alfasigma S.P.A. METHODS FOR TREATING GASTROPARESIA SYMPTOMS USING VELUSETRAG
US10570127B1 (en) 2018-11-05 2020-02-25 Renexxion, Llc Material and methods for the treatment of gastro-intestinal disorders
US20260124194A1 (en) 2022-09-20 2026-05-07 Alfasigma S.P.A. Velusetrag for use in the treatment of chronic intestinal pseudo-obstruction (cipo)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0564650A1 (en) * 1990-12-28 1993-10-13 Kyowa Hakko Kogyo Co., Ltd. Quinoline derivative

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3122671B2 (ja) 1990-05-23 2001-01-09 協和醗酵工業株式会社 複素環式化合物
WO1994012497A1 (fr) 1992-11-20 1994-06-09 Taisho Pharmaceutical Co., Ltd. Compose heterocyclique
JP3829879B2 (ja) 1994-05-18 2006-10-04 大正製薬株式会社 キノリンカルボン酸誘導体
TW402591B (en) * 1997-07-11 2000-08-21 Janssen Pharmaceutica Nv Monocyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives
US7105195B2 (en) * 2003-07-25 2006-09-12 General Mills, Inc. Reduced trans fat product
ES2338882T3 (es) 2003-11-24 2010-05-13 Pfizer, Inc. Compuestos de acido quinolona-carboxilico que tienen actividad agonista del receptor 5-ht4.
US7728006B2 (en) 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
TWI351282B (en) 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
DE602005016446D1 (de) 2004-11-05 2009-10-15 Theravance Inc 5-HT4-Rezeptoragonistenverbindungen
DE602005014566D1 (de) 2004-11-05 2009-07-02 Theravance Inc Chinolinon-carboxamid-verbindungen
US20060183901A1 (en) 2005-02-17 2006-08-17 Theravance, Inc. Crystalline form of an indazole-carboxamide compound
BRPI0608392A2 (pt) 2005-03-02 2009-12-29 Theravance Inc compostos de quinolinona como agonistas do receptor 5-ht4
TWI377206B (en) * 2005-04-06 2012-11-21 Theravance Inc Crystalline form of a quinolinone-carboxamide compound

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0564650A1 (en) * 1990-12-28 1993-10-13 Kyowa Hakko Kogyo Co., Ltd. Quinoline derivative

Also Published As

Publication number Publication date
JP5230407B2 (ja) 2013-07-10
WO2006108127A3 (en) 2007-01-04
PT1874766E (pt) 2010-11-30
NO339699B1 (no) 2017-01-23
JP2008535848A (ja) 2008-09-04
US7728004B2 (en) 2010-06-01
ES2350495T3 (es) 2011-01-24
NO20075574L (no) 2007-11-02
PL1874766T3 (pl) 2011-02-28
CN101151264B (zh) 2011-07-06
CA2603654C (en) 2014-05-27
WO2006108127A2 (en) 2006-10-12
IL186023A (en) 2011-09-27
US8658671B2 (en) 2014-02-25
US9402840B2 (en) 2016-08-02
CA2603654A1 (en) 2006-10-12
EA012115B1 (ru) 2009-08-28
AR110019A2 (es) 2019-02-13
EA200702161A1 (ru) 2008-04-28
MX2007012438A (es) 2007-12-05
NZ561900A (en) 2010-12-24
CY1111275T1 (el) 2015-08-05
CN101151264A (zh) 2008-03-26
DE602006016586D1 (de) 2010-10-14
IL186023A0 (en) 2008-01-20
MA29403B1 (fr) 2008-04-01
BRPI0610657A2 (pt) 2010-07-13
US20140256769A1 (en) 2014-09-11
HK1110866A1 (en) 2008-07-25
US20100197728A1 (en) 2010-08-05
TW200643020A (en) 2006-12-16
HRP20100629T1 (hr) 2010-12-31
EP1874766A2 (en) 2008-01-09
DK1874766T3 (da) 2010-12-06
EP1874766B1 (en) 2010-09-01
KR20070116988A (ko) 2007-12-11
ZA200708071B (en) 2008-10-29
PE20061310A1 (es) 2007-01-23
JP2012153725A (ja) 2012-08-16
US20160095849A1 (en) 2016-04-07
US20060229332A1 (en) 2006-10-12
ATE479682T1 (de) 2010-09-15
AU2006232129A1 (en) 2006-10-12
KR101322873B1 (ko) 2013-10-30
US9126994B2 (en) 2015-09-08
MY151075A (en) 2014-03-31
AR053208A1 (es) 2007-04-25
SI1874766T1 (sl) 2010-12-31
TWI377206B (en) 2012-11-21

Similar Documents

Publication Publication Date Title
US9402840B2 (en) Crystalline form of a quinolinone-carboxamide compound
AU2005233560B2 (en) Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
EP1807423B1 (en) Quinolinone-carboxamide compounds
US8288550B2 (en) Crystalline form of a benzimidazole-carboxamide medicinal compound
US20060183901A1 (en) Crystalline form of an indazole-carboxamide compound
EP1871772A1 (en) Quinolinone compounds as 5-ht4 receptor agonists
HK1110866B (en) Crystalline form of a quinolinone-carboxamide compound
HK1099019B (en) Quinolinone-carboxamide compounds as 5-ht4 receptor agonists

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: THERAVANCE BIOPHARMA R&D IP, LLC

Free format text: FORMER OWNER WAS: THERAVANCE, INC.

PC Assignment registered

Owner name: ALFASIGMA S.P.A.

Free format text: FORMER OWNER(S): THERAVANCE BIOPHARMA R&D IP, LLC

MK14 Patent ceased section 143(a) (annual fees not paid) or expired